by David Rosenblum, MD
David Rosenblum, MD, creator of PainExam.com and Director of Pain Management at New York Based, AABP Pain Management discusses Pain Board Review and issues relevant to pain physicians. Marketing, practice management and Board Prep are discussed. For more information and CME Credit's go to PainExam.com Also, be sure to check out Dr. Rosenblum's children's book: Welwyn Ardsley and the Cosmic Ninjas: Preparing your child and yourself for anesthesia and surgery. Available at Amazon.com and www.MyKidsSurgery.com
Language
🇺🇲
Publishing Since
1/22/2015
Email Addresses
1 available
Phone Numbers
0 available
April 17, 2025
<h1><strong>Summary</strong></h1> <p>At some point this medication may show its face on the pain boards. Whether or not Suzetrigine will appear on the pain boards, all of us need to know about this new class of analgesic.</p> <p>Brought to you by NRAP Academy, home of the <a href= "https://www.nrappain.org/pages/pain-management-cme-courses" target="_blank" rel="noopener">PainExam Board Prep</a></p> <p>Here, Dr. David Rosenblum delivered a comprehensive lecture about a new pain medication called Journavx (Suzetrigine). He discussed its mechanism of action as a NAV 1.8 receptor inhibitor, its clinical applications, contraindications, and dosing guidelines. Dr. Rosenblum emphasized that this non-opioid medication represents a new class of pain management drugs with no addiction potential. He also shared information about upcoming educational events, including ultrasound courses and various pain management conferences. The lecture included detailed information about drug interactions, safety considerations, and clinical trial results comparing Journavx to placebo and hydrocodone-acetaminophen combinations. Key findings from clinical trials showed that Jornavix achieved pain relief in 119 minutes compared to 480 minutes for placebo in abdominoplasty trials, and 240 minutes versus 480 minutes in bunionectomy trials. The recommended dosing is 50mg tablets twice daily, with an initial loading dose of 100mg. While the drug showed promising results for moderate to severe acute pain management, it did not demonstrate superiority over hydrocodone in clinical trials. Important contraindications include CYP3A inhibitors, and special considerations are needed for patients with hepatic impairment or those taking hormonal contraceptives. The medication should be taken on an empty stomach, either one hour before or two hours after food, and patients should avoid grapefruit juice while on this medication.</p> <p><a href="https://pi.vrtx.com/files/uspi_suzetrigine.pdf" target= "_blank" rel="noopener">For more infomation....</a></p> <h1><strong>Chapters</strong></h1> <h2><strong>Introduction and Upcoming Events</strong></h2> <p>Dr. Rosenblum announced several upcoming events, including an ultrasound course in New York City on May 17th, 2025. He mentioned offering ultrasound and IV training for healthcare professionals, particularly nurses, ICUs, PAs, and hospital doctors. He also highlighted upcoming conferences including ASPN, Pain Week, Latin American Pain Society, New York, New Jersey Pain Congress, ASIPP, and EPA.</p> <h2><strong>Introduction to Journavx (Suzetrigine)</strong></h2> <p>Dr. Rosenblum introduced Suzetrigine (Journavx), a new 50mg tablet medication. He emphasized that this discussion was not sponsored by any pharmaceutical company but rather focused on educating about a new class of pain medication. He noted its potential importance as a future board examination topic.</p> <h2><strong>Mechanism of Action</strong></h2> <p>Dr. Rosenblum explained that Jornavx works by inhibiting the NAV 1.8 receptor. He detailed how the drug blocks sodium ions from entering pain-sensing neurons, disrupting action potential initiation and propagation. He emphasized that the drug is highly selective, binding over 31,000 times more selectively to NAV 1.8 than other NAV subtypes.</p> <h2><strong>Contraindications and Drug Interactions</strong></h2> <p>Dr. Rosenblum outlined various contraindications, particularly focusing on CYP3A inhibitors and inducers. He listed specific medications in each category and emphasized the importance of careful monitoring when prescribing Journavx alongside these medications.</p> <h2><strong>Clinical Trial Results and Dosing Guidelines</strong></h2> <p>Dr. Rosenblum presented clinical trial results showing Journavx's effectiveness in treating moderate to severe acute pain. He detailed the dosing guidelines: 50mg tablets twice daily, with an initial loading dose of 100mg. He emphasized the importance of taking the medication on an empty stomach and avoiding grapefruit juice.</p> <h1><strong>Q&A</strong></h1> <p>No Q&A session in this lecture</p>
March 31, 2025
<h1><strong>Summary</strong></h1> <p>The video covers a conversation between Dr. David Rosenblum and Dr. Hamed Sadeghipour, discussing board preparation experiences and the current state of pain management practice. Dr. Rosenblum begins by announcing upcoming events, including a May 17th ultrasound course in New York City and his lectures at various conferences. He also mentions shadowing opportunities at his office. Dr. Sadeghipour shares his board preparation experience, discussing three main resources he used: Huntoon book (800 questions), Board Vitals (700 questions), and Pain Exam. He achieved notably high scores using these resources. Regarding his current practice, Dr. Sadeghipour describes working both in academic anesthesia (40-50% time) and private pain practice, managing four offices with four nurse practitioners. The discussion then shifts to the changing landscape of pain management, with both doctors noting concerning trends: increasing focus on surgery center procedures over office-based ones due to reimbursement differences, the challenge of maintaining competency in advanced procedures, and competition from non-specialists entering the field. They also discuss the future of the specialty, suggesting it's moving toward becoming a hybrid of neurosurgery and orthopedic surgery with traditional pain management procedures.</p> <p> </p> <p>For pain medicine Board Prep go to <a title= "Pain Management Board Prep" href= "https://www.painexam.com">NRAPpain.org</a></p> <p>For ultraound training go to <a title= "Ultrasound Guided Interventional Pain and Regional Anesthesia" href= "https://www.nrappain.org/pages/ultrasound-course-calendar">NRAP Academy</a></p> <h1><strong>Highlights</strong></h1> <h2><strong>Introduction and Upcoming Events</strong></h2> <p>Dr. Rosenblum introduces the podcast and announces several upcoming events, including an ultrasound course in New York City on May 17th, appearances at ASPN and Pain Week conferences, and opportunities for shadowing at his practice.</p> <h2><strong>Board Preparation Experience Discussion</strong></h2> <p>Dr. Sadeghipour details his board preparation strategy using three main resources: Huntoon book (800 questions), Board Vitals (700 questions), and Pain Exam(700 questions videos, lectures, ultrasound training, regenerative medicine training and more). He explains the strengths and limitations of each resource and mentions achieving exceptionally high scores.</p> <h2><strong>Current Practice Structure</strong></h2> <p>Dr. Sadeghipour describes his dual practice model: </p> <h2><strong>Evolution of Pain Management Practice</strong></h2> <p>Both doctors discuss the shifting landscape of pain management, noting increased focus on surgery center procedures, reimbursement challenges, and competition from non-specialists. They address concerns about fellowship training adequacy and the financial pressures affecting new practitioners.</p> <h2><strong>Future of Pain Management Specialty</strong></h2> <p>The discussion concludes with perspectives on the specialty's future, suggesting it's evolving toward a combination of minimally invasive spine surgery and traditional pain management, with concerns about maintaining specialty integrity and the need for stronger regulatory oversight.</p>
March 12, 2025
<p>Dr. Rosenblum Reviews Questions from my previous lecture, he gave at the trigeminal academy in Indonesia.</p> <p>Dr. Rosenblum explores techniques for rich plasma injection and preparation. He discusses centrifuge settings with plasma volume and concentration as well as the addition of hyaluronic acid to platelet rich plasma.</p> <p>Dr. Rosenb;um also received multiple comments on the recent video that he filmed on performing a cervical selective nerve root block under ultrasound. </p> <p>For more informatin go to NRAPpain.org</p> <p> </p> <p class="p1"> </p> <p class="p2">Disclaimer: This Podcast,video, website and any content from NRAP Academy otherwise known as Qbazaar.com, LLC is<span class= "Apple-converted-space"> </span> for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.</p>
American Society of Pain & Neuroscience
Brian Joves, M.D.
Dr. Jim Dahle of the White Coat Investor
American Society of Regional Anesthesia and Pain Medicine
All-In Podcast, LLC
Peter Attia, MD
Justin Harvey
The New York Times
Jason Bateman, Sean Hayes, Will Arnett
Vox Media Podcast Network
Brian Preston and Bo Hanson
NPR
The Ringer
Vox Media Podcast Network
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.